RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-5216
Malaria parasiteP. berghei
Genotype
TaggedGene model (rodent): PBANKA_0901300; Gene model (P.falciparum): PF3D7_1147800; Gene product: membrane associated erythrocyte binding-like protein (MAEBL)
Name tag: c-myc
Transgene
Transgene not Plasmodium: A fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
Phenotype Sporozoite;
Last modified: 20 June 2022, 15:55
  *RMgm-5216
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene tagging, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 35628522
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 676m1cl1 (RMgm-29)
Other information parent line676m1cl1 (RMgm-29) is a reference ANKA mutant line that expresses GFP-luciferase under control of a constitutive promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190).
The mutant parasite was generated by
Name PI/ResearcherSá M, Tavares J
Name Group/DepartmentHost-Parasite Interactions Group, Instituto de Investigação e Inovação em Saúde
Name InstituteUniversidade do Porto
CityPorto
CountryPortugal
Name of the mutant parasite
RMgm numberRMgm-5216
Principal namemaebl:myc
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationNo
Phenotype
Asexual blood stageNot tested
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteAnalyses of the mutant expressing a C-terminal cmyc tagged version of MAEBL showed expression in micronemes of sporozoites (with higher expression in hemolymph sporozoites compared to salivary gland sporozoites).
Immunoelectron microscopy analyses provided evidence that myc-tagged MAEBL was detected not only associated with micronemes but also to the surface of sporozoites, i.e., near the plasma membrane and/or inner membrane complex
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant expresses a C-terminal cmyc-tagged version of MAEBL and expresses the fusion protein GFP-Luciferase under control of the constitutive eef1a promoter

Protein (function)
MAEBL is a large type I transmembrane protein composed of two N-terminal cysteine-rich adhesion domains homologous to the apical membrane antigen 1 (AMA-1), named M1 and M2, and a C-terminal cysteine-rich region (C-cys) structurally related with Plasmodium Duffy binding-like family of erythrocyte binding proteins. Conserved among Plasmodium species, MAEBL was initially reported as an erythrocytic-binding protein present in blood-stage parasites, but was later found to be expressed in sporozoites and late liver stages. In sporozoites, MAEBL is found associated with the micronemes. 

Phenotype

Analyses of the mutant expressing a C-terminal cmyc tagged version of MAEBL showed expression in micronemes of sporozoites (with higher expression in hemolymph sporozoites compared to salivary gland sporozoites). Partial co-localization with thrombospondin related anonymous protein (TRAP) was frequently observed in midgut and hemolymph sporozoites, confirming the micronemal localization ofMAEBL. However, colocalization with TRAP in salivary gland sporozoites was not as evident in some sporozoites, as TRAP was frequently found uniformly spread over the sporozoite surface, unlike myc-tagged MAEBL. Immunoelectron microscopy analyses provided evidence that myc-tagged MAEBL was detected not only associated with micronemes but also to the surface of sporozoites, i.e., near the plasma membrane and/or inner membrane complex.

Additional information

Other mutants


  Tagged: Mutant parasite with a tagged gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0901300
Gene Model P. falciparum ortholog PF3D7_1147800
Gene productmembrane associated erythrocyte binding-like protein
Gene product: Alternative nameMAEBL
Details of the genetic modification
Name of the tagc-myc
Details of taggingC-terminal
Additional remarks: tagging
Commercial source of tag-antibodies
Type of plasmid/construct(Linear) plasmid single cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe transfection vector containing the tagged maebl ORF was obtained through modification of the pL0007_MAEBLcomp plasmid by inserting a sequence encoding 2 copies of the myc tag epitope (2 EQKLISEEDL) right before the stop codon. The maebl 3'UTR (497 bp) and the last 669 bp of the maebl ORF (excluding the stop codon) were amplified using the primer pairs P5/P9 and P10/P11, respectively; the latter primer including the coding sequence of the tag. Both fragments were subcloned into the XhoI/EcoRV and EcoRV/EcoRI sites of a pL0007 vector, originating the plasmid pL0007_MAEBLmyc_3'UTR. The pL0007_MAEBLcomp plasmid was digested with the BstBI restriction enzyme to remove a 6689 bp fragment corresponding to the last 13 bp of the PBANKA_0901400 gene sequence, the entire maebl 5'UTR and the first 5475 bp of the maebl ORF, henceforth named 5'UTR_ORF fragment. After religation, the resultant plasmid was digested with BstBI/HincII to replace the maebl 3'UTR and the final portion of the maebl ORF by a myc-tagged version, obtained through the digestion of pL0007_MAEBLmyc_3'UTR with the same restriction enzymes. Finally, the plasmid was digested with BstBI to allow the insertion of the 5'UTR_ORF fragment, originating the final transfection vector. The correct orientation of the insert and the presence of the myc tag epitope coding sequence in the transfection vector were confirmed by DNA sequencing. The plasmid was linearized with PmeI before transfection.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameA fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) PCR construct double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitegfp (FACS)
Promoter of the selectable markereef1a
Selection (positive) procedureFACS (flowsorting)
Selection (negative) procedureNo
Additional remarks genetic modificationThe GFP-Luciferase gene (1 copy) has been inserted into the 230p locus (PB000214.00.0) by double cross-over integration
Additional remarks selection procedureThis reporter mutant expressing GFP-Luciferase does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4